EFFICACY OF AMIKACIN AND CIPROFLOXACIN AGAINST CLINICAL ISOLATES OF MYCOBACTERIUM TUBERCULOSIS
AbstractBackground: Tuberculosis was a leading cause of death at the turn of the 20th century and continues tobe one of the medical scourges of mankind. Before the availability of antimicrobial drugs thecornerstone of treatment was rest in the open air in sanatoria. The major breakthrough in treatment oftuberculosis came with the discovery of Streptomycin. Later, INH, Ethambutol, Pyrazinamide,Rifampicin were added to the arsenal. Objective of this study was to determine the sensitivity of clinicalisolates of Mycobacterium tuberculosis against two second-line anti-tuberculosis drugs, Amikacin andCiprofloxacin. Methods: This cross-sectional study was conducted at Department of Microbiology,Armed Forces Institute of Pathology (AFIP) Rawalpindi. All routine clinical samples received for acidfast bacilli (AFB) in the Department of Microbiology, AFIP, Rawalpindi were processed by modifiedPetroff’s technique and inoculated on Lowenstein Jensen (LJ) medium and Bactec 460 Mycobacteriumtuberculosis culture system. After identification of M. tuberculosis sensitivity was performed againstfirst-line anti-tuberculosis drugs. Then susceptibility of M. tuberculosis isolates against Amikacin andCiprofloxacin was performed on LJ medium. H37Rv was used as control strain. Results: Results wereinterpreted using resistance ratio method. Out of 100 M. tuberculosis isolates, 98% were sensitive toAmikacin and 97% to Ciprofloxacin. Conclusion: Amikacin and Ciprofloxacin are very effective 2ndline anti-tuberculosis drugs against tuberculosis isolates in our set-up.Keywords: Tuberculosis, MDR-tuberculosis, susceptibility, second-line anti-tuberculosis drugs
Kochi A. The global tuberculosis situation and the newer
control strategy of the world health organization. Tubercle
;72:1–6. Reproduced: Bull World Health Organization
Haas DW, Prez RMD. Mycobacterial Diseases. In: Mandell
GL, Benett JE, Dolin R. (eds). Mandell Douglas and Benett’s
Principle and Practice of infectious diseases, 6th ed. New
York: Churchill Livingstone;2005.p.2213–43.
Salfinger. HM, Hale YM, Driscoll JR. Diagnostic tools in
tuberculosis. Respiration 1998;65:63–170.
Doren GV. Diagnostic mycobacteriology; where are we
today? J Clin Microbiol 1996;34:1873–6.
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S,
Krapp F, et al. Rapid molecular detection of tuberculosis and
rifampin resistance. NEJM 2010;363:1005–15.
Croften SJ, Chaulet P, Maher D. Guidelines for the
management of drug resistant tuberculosis. World Health
Organization, Geneva 1997;WHO/TB/96.210:1–47.
Karamat KA, Hayat S, Butt T, Abbasi S. Multidrug resistant
tuberculosis. Pak Armed F Med J 2000;50(2):114–6.
Heymann SJ, Brewer TF, Wilson ME, Fineberg HV. The
need for global action against multidrug resistant
tuberculosis. JAMA 1999;281:2138–41.
Raviglione MC, Smith IM. XDR tuberculosis–Implications
for global public health. N Engl J Med 2007;356:656–9.
Laidlaw M. Mycobacterium tubercle bacilli. In: Collee JG,
Duguid JP, Frazer AG, Marmion BP (eds). Mackie & Mc
Cartney Practical Medical Microbiology. 14th ed. London:
Ruiz-Serrano MJ, Alcalá L, Martínez L, Díaz M, Marín M,
González-Abad MJ, et al. In vitro activities of six
fluoroquinolones against 250 clinical isolates of M.
tuberculosis susceptible or resistant to first line
antituberculosis drugs. Antimicrobe Agents Chemother
Rastogi N, Labrousse V, Goh KS. In vitro activities of
fourteen antimicrobial agents against drug susceptible and
resistant clinical isolates of M. tuberculosis and comparative
intracellular activities against the virulent H37Rv strain in
human macrophages. Curr Microbiol 1996;33:167–75.
Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S.
Comparative antimicrobial activity of the newly synthesized
quinolones WQ-3034, levofloxacin,. sparfloxacin and
ciprofloxacin against Mycobacterium tuberculosis and
Mycobacterium avium complex. Antimicrobial Agents
Fattorini L, Iona E, Ricci ML, Thoresen OF, Orru G, Oggioni
MR, et al. Activity of 16 antimicrobial agents against drugresistant strains of Mycobacterium tuberculosis. Microb Drug
Hoffner SE, Gezelius L, Liljequist BO. In vitro activity of
fluorinated quinolones and macrolides against drug resistant M.
tuberculosis. J Antimicrobiol Chemother 1997;40:885–88.
Alangaden GJ, Lerner SA. The clinical use of
fluoroquinolones for the treatment of mycobacterial disease.
Clin Infec Dis 1997;25:1213–21.
Hoffner SE, Kallenius G. Susceptibility of streptomycin
resistant M. tuberculosis strains to amikacin. Eur J Clin
Microbiol Infec Dis 1988;7:188–90.
Pfyffer GE, BonatoDA, Ebrahimzadeh A, Gross W, Hotaling
J, Kornblum J, et al. Multicentre laboratory validation of
susceptibility testing of M. tuberculosis against classical
second-line and newer antimicrobial drugs by using the
radiometric Bactec 460 technique and the proportion method
with solid media. J Clin Microbiol 1999;37:3179–86.